Has Frank Pitruzzello, MD received payments from drug or device companies?

Yes. Drug and device makers reported $5,889 in general payments to Frank Pitruzzello, MD across 337 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Frank Pitruzzello, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Frank Pitruzzello, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Frank Pitruzzello, MD

Radiation Oncology · Mobile, ALNPI 1003820697

Payments from drug & device makers

$5,889in general payments, 2019–2025

Across 337 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$771
AstraZeneca$723
Merck$449
Incyte Corporation$371
Eisai Inc.$345
Johnson & Johnson$282
plus $3K from 48 others

What the payments were for

Food & beverage$5,85899%
Education$311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	42	$771
AstraZeneca(2 entities)	48	$723
Merck	23	$449
Incyte Corporation	21	$371
Eisai Inc.	20	$345
Johnson & Johnson(2 entities)	17	$282
Daiichi Sankyo Inc.	15	$259
Amgen	15	$240
Regeneron Healthcare Solutions, Inc.	9	$211
Genentech USA, Inc.	8	$178
Astellas Pharma US Inc	8	$139
Sanofi	6	$126
Lilly USA, LLC	8	$120
Tersera Therapeutics LLC	3	$103
Puma Biotechnology, Inc.	6	$99
Stemline Therapeutics Inc.	4	$90
Ipsen Biopharmaceuticals, Inc	5	$89
Takeda Pharmaceuticals U.S.A., Inc.	5	$84
Exelixis Inc.	5	$79
Bayer	4	$72
Servier Pharmaceuticals LLC	4	$66
Boehringer Ingelheim	3	$61
Novocure Inc.	3	$58
Sobi, Inc	3	$54
Acceleron Pharma, Inc.	3	$47
AMAG Pharmaceuticals, Inc.	3	$44
Beigene USA, Inc.	3	$42
Morphosys, US Inc.	3	$40
Pharmaessentia USA Corporation	2	$40
Karyopharm Therapeutics Inc.	3	$39
Seagen Inc.	2	$39
Genmab U.S., Inc.	2	$37
GSK	2	$37
Beone Medicines USA, Inc.	2	$35
Coherus Oncology, Inc.	2	$35
Clovis Oncology, Inc.	3	$31
Mirati Therapeutics, Inc.	2	$31
E.r. Squibb & Sons, L.L.C.	2	$28
Taiho Oncology, Inc.	2	$27
Tempus AI, Inc	1	$26
Rigel Pharmaceuticals, Inc.	2	$26
Jazz Pharmaceuticals Inc.	1	$24
Emmaus Medical, Inc.	1	$24
Teleflex LLC	1	$23
AVEO Pharmaceuticals, Inc.	1	$18
Apellis Pharmaceuticals, Inc.	1	$18
Agios Pharmaceuticals, Inc.	1	$17
Shire North American Group Inc	1	$14
Cumberland Pharmaceuticals, Inc.	1	$14
Epizyme, Inc.	1	$13
Partner Therapeutics, Inc.	1	$13
Veracyte, Inc.	1	$13
G1 Therapeutics, Inc.	1	$12
Pharmacyclics LLC, An Abbvie Company	1	$12

How this compares

$5,889 in reported general payments places this provider in the 80th percentile of 87 radiation oncology providers in Alabama.

See all radiation oncology providers in Alabama →

Medicare billing

Part B allowed, 2024

$327,501

Medicare patients

Services billed

1,690

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dexamethasone	33	$522

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Mobile

John RussellMobile$27K
Joseph JonesMobile$5K
James GalleMobile$4K
Olivia BallMobile$2K
Adam HuddlestonMobile$766
John RovedaMobile$713
Robert GilbertMobile$458
Alexander WhitleyMontgomery$458K
Andrew McDonaldBirmingham$256K
Christopher WilleyBirmingham$213K

See the full list for Alabama →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →